Pfizer Inc.’s Stake In Cellectis’ Capital Is Welcomed By Its Shareholders

PARIS--(BUSINESS WIRE)--Regulatory News:The Extraordinary General Shareholders’ Meeting of Cellectis (Alternext: ALCLS) was held on Thursday July 31, 2014 in Paris, at the Group’s headquarters . This meeting had been convened to take a decision on a planned 25,779,047 euros capital increase through the issuance of 2,786,924 new ordinary shares (corresponding to a total par value of 139,346.20 euros) and the suppression of shareholders’ preferential subscription rights in favor of Pfizer.

Help employers find you! Check out all the jobs and post your resume.